Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDMONASDAQ:CMRXNASDAQ:ETNBNASDAQ:KMPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDMOAvid Bioservices$12.50+0.1%$12.50$6.61▼$12.51$799.18M1.391.43 million shs3.07 million shsCMRXChimerix$8.54$8.54$0.75▼$8.55$801.09M-0.172.65 million shsN/AETNB89BIO$10.08+0.8%$8.54$4.16▼$11.84$1.46B1.31.52 million shs3.07 million shsKMPHZevra Therapeutics$5.51$4.00▼$6.92$200.47M2.16189,500 shs64,100 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDMOAvid Bioservices0.00%0.00%0.00%0.00%+67.94%CMRXChimerix0.00%0.00%0.00%+0.47%+879.36%ETNB89BIO+0.80%-3.17%+4.89%+18.31%+20.00%KMPHZevra Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDMOAvid Bioservices0.6576 of 5 stars1.00.00.04.50.01.70.6CMRXChimerix0.6787 of 5 stars1.00.00.04.10.61.70.6ETNB89BIO2.5587 of 5 stars3.53.00.00.02.80.80.6KMPHZevra TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDMOAvid Bioservices 2.00Hold$12.25-1.96% DownsideCMRXChimerix 2.00Hold$8.53-0.08% DownsideETNB89BIO 3.00Buy$26.43162.19% UpsideKMPHZevra Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest KMPH, ETNB, CMRX, and CDMO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/24/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/10/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/30/2025ETNB89BIOCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/24/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/8/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)3/22/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDMOAvid Bioservices$139.91M5.71$0.15 per share80.92$3.02 per share4.14CMRXChimerix$212K3,778.71N/AN/A$2.17 per share3.94ETNB89BION/AN/AN/AN/A$3.34 per shareN/AKMPHZevra Therapeutics$10.72M0.00N/A23.28$3.63 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDMOAvid Bioservices-$140.75M-$2.39N/AN/AN/A-101.07%-33.18%-8.45%6/30/2025 (Estimated)CMRXChimerix-$82.10M-$0.99N/AN/AN/AN/A-50.78%-44.94%8/11/2025 (Estimated)ETNB89BIO-$367.08M-$3.38N/AN/AN/AN/A-81.44%-70.17%8/4/2025 (Estimated)KMPHZevra Therapeutics-$8.56MN/A0.00N/AN/A-328.56%-16.12%-14.17%N/ALatest KMPH, ETNB, CMRX, and CDMO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025ETNB89BIO-$0.50-$0.49+$0.01-$0.49N/AN/A3/21/2025Q4 2024CMRXChimerix-$0.26-$0.25+$0.01-$0.25$0.31 million$0.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDMOAvid BioservicesN/AN/AN/AN/AN/ACMRXChimerixN/AN/AN/AN/AN/AETNB89BION/AN/AN/AN/AN/AKMPHZevra TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDMOAvid Bioservices3.581.300.92CMRXChimerixN/A6.336.33ETNB89BIO0.0618.0318.03KMPHZevra Therapeutics0.1410.1010.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDMOAvid Bioservices97.16%CMRXChimerix45.42%ETNB89BION/AKMPHZevra Therapeutics19.39%Insider OwnershipCompanyInsider OwnershipCDMOAvid Bioservices3.05%CMRXChimerix13.10%ETNB89BIO2.60%KMPHZevra Therapeutics1.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDMOAvid Bioservices32063.96 million62.01 millionOptionableCMRXChimerix9093.80 million78.15 millionOptionableETNB89BIO40145.98 million142.19 millionOptionableKMPHZevra Therapeutics2234.51 million34.13 millionOptionableKMPH, ETNB, CMRX, and CDMO HeadlinesRecent News About These CompaniesZevra Cashes in on First FDA-Approved NPC Treatment with PRVMay 24, 2025 | genengnews.comZevra Therapeutics signals accelerated MIPLYFFA adoption and $148.3M capital infusion while expanding global reachMay 14, 2025 | msn.comZevra Therapeutics closes sale of Rare Disease PRV for $150MApril 8, 2025 | markets.businessinsider.comZevra Therapeutics price target raised to $25 from $23 at CanaccordMarch 13, 2025 | markets.businessinsider.comZevra Therapeutics price target raised to $22 from $20 at GuggenheimMarch 13, 2025 | markets.businessinsider.comZevra Therapeutics embarks on diagnosis push as Miplyffa launch gains steamMarch 13, 2025 | fiercepharma.comZevra Therapeutics reports Q4 EPS (67c), consensus (40c)March 12, 2025 | markets.businessinsider.comZevra Therapeutics to Sell Priority-Review Voucher for $150 MillionFebruary 27, 2025 | marketwatch.comZevra Therapeutics to sell Rare Pediatric Disease PRV for $150MFebruary 27, 2025 | markets.businessinsider.comZevra to net $150M from priority review voucher sale tied to Miplyffa approvalFebruary 27, 2025 | fiercepharma.comZevra Therapeutics (ZVRA) Gets a Buy from Roth MKMFebruary 10, 2025 | markets.businessinsider.comZevra Therapeutics price target raised to $21 from $20 at GuggenheimFebruary 4, 2025 | markets.businessinsider.comZevra Therapeutics to be added to Nasdaq Biotechnology IndexDecember 18, 2024 | markets.businessinsider.comZevra Therapeutics Gains Buy Rating Amid Successful MIPLYFFA Launch and Strong Market ResponseNovember 22, 2024 | markets.businessinsider.comZevra Therapeutics announces U.S. commercial availability of MIPLYFFANovember 21, 2024 | markets.businessinsider.comZevra Therapeutics Gains Momentum with Miplyffa Approval and Market Expansion Potential in Rare Disease TreatmentNovember 21, 2024 | markets.businessinsider.comZevra Therapeutics: Buy Rating Backed by Strong Pipeline and Experienced Leadership in Rare Disease MarketNovember 19, 2024 | markets.businessinsider.comZevra Therapeutics: Promising Launch Prospects and Strategic Initiatives Drive Buy RatingNovember 14, 2024 | markets.businessinsider.comZevra Therapeutics price target lowered to $23 from $25 at CanaccordNovember 14, 2024 | markets.businessinsider.comZevra Therapeutics (ZVRA) Receives a Buy from Roth MKMNovember 14, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKMPH, ETNB, CMRX, and CDMO Company DescriptionsAvid Bioservices NASDAQ:CDMO$12.50 +0.02 (+0.12%) Closing price 02/5/2025Extended Trading$12.50 0.00 (0.00%) As of 02/5/2025 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.Chimerix NASDAQ:CMRX$8.54 0.00 (0.00%) As of 04/21/2025Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.89BIO NASDAQ:ETNB$10.08 +0.08 (+0.80%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$10.34 +0.26 (+2.58%) As of 06/20/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Zevra Therapeutics NASDAQ:KMPHKemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
